Literature DB >> 10613354

Telomere-related components are coordinately synthesized during human T-lymphocyte activation.

B A Kosciolek1, P T Rowley.   

Abstract

Since telomerase activity is present in most malignant cells, but absent in most normal cells, its induction in normal cells warrants scrutiny. Therefore we have analyzed the inducibility of telomere-related components in normal lymphocytes during their activation. Telomerase activity increased over 400-fold, telomerase reverse transcriptase (hTERT) mRNA 52 x , telomerase RNA 32 x , TTAGGG repeat binding factor 1 mRNA 19 x , TTAGGG repeat binding factor 2 mRNA 20 x , and telomerase-associated protein mRNA 17 x . The peak value for each was reached at about 72 h. However hTERT rose fastest and synchronously with telomerase activity. Thus in normal human lymphocytes (1) the syntheses of all cloned telomerase-related components are coordinately regulated and (2) hTERT may have a priming role.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613354     DOI: 10.1016/s0145-2126(99)00134-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity.

Authors:  Francesca S Gazzaniga; Elizabeth H Blackburn
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

2.  Detection of telomerase activity and the expression of telomerase subunits in the patients with acute myelogenous leukaemia.

Authors:  Yirong Li; Jianming Wu; Lin Wang; Fenghua Chen; Lihua Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Interferon alpha on expression of hTERT mRNA in peripheral blood mononuclear cells of patients with chronic hepatitis B.

Authors:  Chuan-wu Zhu; Ming Chen; Xiang-rong Luo; Hai-yan Wang; Li-hua Wang; Jian-hong Wu; Ming Li; Xue-hua Zhang; Wei Zhu; Jian-zhong Ye; Feng Qian
Journal:  Clin Dev Immunol       Date:  2011-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.